152 results found.

Healthy Clinical Trial using BI 655075; Placebo to dose; Placebo to BI 655075; dabigatran

Boehringer Ingelheim - Recruiting 20 years to 45 years.
- Randomised, Double-blind Within Dose Groups, Placebo-controlled Phase I Trial in Healthy Japanese Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Different Doses of BI 655075 (Part 1) and to Explore the Effective Dose of BI 655075 to Reverse Dabigatran Anticoagulant Activity (Part 2)..
BI 655075; Placebo to dose; Placebo to BI 655075; dabigatran

Traumatic Brain Injury, or Healthy Clinical Trial using PET

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- PET Imaging of Translocator Protein in Subjects With Traumatic Brain Injury.
PET

Inflammatory Disease, Autoimmune Disease, Immunologic Disease, or Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols.

Healthy Clinical Trial using 0.15 mg PF-06649751; 0.5 mg PF-06649751; 1.5 mg PF-06649751; 1.0 mg PF-06649751; TBD mg PF-06649751

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06649751 In Healthy Subjects.
0.15 mg PF-06649751; 0.5 mg PF-06649751; 1.5 mg PF-06649751; 1.0 mg PF-06649751; TBD mg PF-06649751

Healthy Clinical Trial using Faldaprevir; Cyclosporine; Tacrolimus

Boehringer Ingelheim - Recruiting 18 years to 50 years.
- Investigation of Potential Drug-drug Interactions Between Faldaprevir and Immunosuppressants (Cyclosporine and Tacrolimus) in Healthy Male and Female Subjects (Open-label, Fixed-sequence Trial).
Faldaprevir; Cyclosporine; Tacrolimus

Healthy Clinical Trial using itraconazole; BI 691751

Boehringer Ingelheim - Recruiting 18 years to 50 years.
- Relative Bioavailability of a Single Oral Dose of BI 691751 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Study).
itraconazole; BI 691751

Healthy Volunteers Clinical Trial using JNJ-38877618: Part 1a; JNJ-38877618: Part 1b; JNJ-38877618: Part 1c (optional); JNJ-38877618: Part 2; JNJ-38877618: Part 3; JNJ-38877618: Part 4 (optional); Placebo: Parts 1a, 2, 3, and 4 (optional)

Janssen Cilag N.V./S.A. - Recruiting 18 years to 65 years.
- A Double Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Subjects.
JNJ-38877618: Part 1a; JNJ-38877618: Part 1b; JNJ-38877618: Part 1c (optional); JNJ-38877618: Part 2; JNJ-38877618: Part 3; JNJ-38877618: Part 4 (optional); Placebo: Parts 1a, 2, 3, and 4 (optional)

Crohn's Disease Clinical Trial using AMG 139

Amgen - Recruiting 18 years to 55 years.
- A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease.
AMG 139

Effect of Atorvastatin on the Pharmacokinetics of Lomitapide Clinical Trial using lomitapide; Atorvastatin

Aegerion Pharmaceuticals, Inc. - Recruiting 18 years to 55 years.
- A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Atorvastatin, a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Subjects.
lomitapide; Atorvastatin

Healthy Clinical Trial using lomitapide; EE/norgestimate

Aegerion Pharmaceuticals, Inc. - Recruiting 18 years to 40 years.
- A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Ethinyl Estradiol/Norgestimate (Ortho Cyclen®), a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Female Subjects.
lomitapide; EE/norgestimate

Atrial Fibrillation, or Acute Coronary Syndrome Clinical Trial using Ticagrelor + Apixaban + ASA; Ticagrelor + Apixaban

Medical University of Vienna - Recruiting 18 years to 40 years.
- The Effect of Ticagrelor and Apixaban With or Without Acetylsalicylic Acid on Markers of Coagulation Activation at the Site of Thrombus Formation in Vivo in Healthy Male Subjects and in an ex Vivo Perfusion Chamber Model at High and Low Shear Rate.
Ticagrelor + Apixaban + ASA; Ticagrelor + Apixaban

Healthy Volunteers Clinical Trial using LY2605541; Insulin Lispro

Eli Lilly and Company - Recruiting 21 years to 65 years.
- A Phase 1 Study to Evaluate the Pharmacokinetics of LY2605541 Injection and Insulin Lispro Injection Administered as Mixture or as Individual Components in Healthy Subjects.
LY2605541; Insulin Lispro

Healthy Clinical Trial using PF-06678552 or Placebo

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-06678552 After Fed And Fasted Administration Of Single Escalating Oral Doses In Healthy Subjects.
PF-06678552 or Placebo

Healthy Clinical Trial using Canagliflozin; Dapagliflozin

Janssen-Cilag International NV - Recruiting 18 years to 55 years.
- A Double-Blind, Randomized, 2-Way Crossover Study to Compare the Pharmacodynamics of Canagliflozin 300 mg Versus Dapagliflozin 10 mg in Healthy Subjects.
Canagliflozin; Dapagliflozin

Healthy Volunteers and Asthma Clinical Trial using CNTO 3157 (healthy participants); Placebo (healthy participants); CNTO 3157 (asthmatic patients); Placebo (asthmatic patients); HRV-16

Janssen Research & Development, LLC - Recruiting 18 years to 65 years.
- A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated With Human Rhinovirus Type 16.
CNTO 3157 (healthy participants); Placebo (healthy participants); CNTO 3157 (asthmatic patients); Placebo (asthmatic patients); HRV-16

Healthy Volunteer Clinical Trial using ipatasertib (Tablet); ipatasertib (Capsule)

Genentech - Recruiting 18 years to 55 years.
- A Phase 1, Open-Label Study to Evaluate the Effect of Formulation on the Bioavailability of Ipatasertib (GDC-0068) in Healthy Subjects.
ipatasertib (Tablet); ipatasertib (Capsule)

Healthy Subjects With Different Constitutions Clinical Trial using Coconut water; ginger tea

National Taiwan University Hospital - Recruiting 20 years to 65 years.
- Investigation of Pulse Waves and Channel Entries Produced in Healthy Subjects With Different Constitutions and Their Changes After Treated With Foods of Different Food Attributes.
Coconut water; ginger tea

Multiple Sclerosis, Weakness, or Fatigue Clinical Trial using Cross-Training healthy subjects; Cross-Training multiple sclerosis; Standard-training multiple sclerosis

Università degli Studi di Sassari - Recruiting 18 years to 65 years.
- Neurophysiological, Dynamometric, Functional and Clinical Assessment of the Cross-Training Effect in Patients With Multiple Sclerosis.
Cross-Training healthy subjects; Cross-Training multiple sclerosis; Standard-training multiple sclerosis

Migraine Clinical Trial using AMG 333; Placebo

Amgen - Recruiting 18 years to 55 years.
- A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 333 in Healthy Subjects and Subjects With Migraines..
AMG 333; Placebo

Mild-Moderate Alzheimer's Disease, or Healthy Elderly Clinical Trial using MEDI1814 for IV injection; MEDI1814 for Subcutaneous Injection; IV Placebo; Placebo for Subcutaneous Injection

AstraZeneca - Recruiting 55 years to 85 years.
- A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease..
MEDI1814 for IV injection; MEDI1814 for Subcutaneous Injection; IV Placebo; Placebo for Subcutaneous Injection

Pharmacokinetics Clinical Trial using Beclomethasone dipropionate BAI; Beclomethasone dipropionate MDI

Teva Pharmaceutical Industries - Recruiting 18 years to 45 years.
- A Randomized, Open-Label, 3-Period Crossover, Single-Dose Clinical Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Beclomethasone Dipropionate (160 and 320 mcg) Delivered Via Breath-Actuated Inhaler (BAI) and Metered-Dose Inhaler (MDI) in Healthy Adult Subjects.
Beclomethasone dipropionate BAI; Beclomethasone dipropionate MDI

Diabetes, or Healthy Clinical Trial using semaglutide; placebo; moxifloxacin

Novo Nordisk - Recruiting 18 years to 45 years.
- A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects: A Randomised, Double-Blind,Placebo-Controlled, Three-Arm Parallel Trial With a Nested Cross-Over Design for Positive Control With Moxifloxacin Administration.
semaglutide; placebo; moxifloxacin

Healthy Subjects Clinical Trial using RPX7009 and RPX2014

Rempex Pharmaceuticals - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Open-Label, Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous CarbavanceT (RPX2014/RPX7009) in Healthy Adult Subjects.
RPX7009 and RPX2014

Healthy Clinical Trial using JNJ-42165279 (100 mg); Placebo

Janssen Research & Development, LLC - Recruiting 18 years to 45 years.
- The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Subjects.
JNJ-42165279 (100 mg); Placebo

Healthy Clinical Trial using PF-06480605; Placebo

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Double-blind, Third-party Open Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.
PF-06480605; Placebo

Healthy Clinical Trial using 3 mg PF-06412562; 10 mg PF-06412562; 25 mg PF-06412562; PF-06412562 TBD mg

Pfizer - Recruiting 18 years to 55 years.
- Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of PF-06412562 In Healthy Subjects.
3 mg PF-06412562; 10 mg PF-06412562; 25 mg PF-06412562; PF-06412562 TBD mg

Healthy Clinical Trial using PF-06273340; Placebo

Pfizer - Recruiting 18 years to 75 years.
- A Phase 1, Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Doses of PF-06273340 in Healthy Subjects.
PF-06273340; Placebo

COPD, or Healthy Subjects Clinical Trial using AZD7624; Placebo to match

AstraZeneca - Recruiting 18 years to 55 years.
- A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to Healthy Subjects and Patients With COPD.
AZD7624; Placebo to match

Healthy Clinical Trial using PF-06372865 or Placebo; PF-06372865 or Placebo or Lorazepam

Pfizer - Recruiting 18 years to 55 years.
- A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06372865 in Healthy Male and Female Subjects.
PF-06372865 or Placebo; PF-06372865 or Placebo or Lorazepam

Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lu Clinical Trial using Skin biopsy; Blood collection; Urine collection

Janssen Research & Development, LLC - Recruiting 18 years to 70 years.
- Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers.
Skin biopsy; Blood collection; Urine collection

Healthy Volunteers Clinical Trial using LY2835219

Eli Lilly and Company - Recruiting 18 years to 65 years.
- Effect of Food on the Pharmacokinetics of LY2835219 in Healthy Subjects.
LY2835219

Healthy Volunteer Clinical Trial using tocilizumab [RoActemra/Actemra]; placebo

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Single Blind Phase IV Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose Tocilizumab Treatment in Healthy Subjects.
tocilizumab [RoActemra/Actemra]; placebo

Major Depressive Disorder Clinical Trial using LY03005; Placebo

Luye Pharma Group Ltd. - Recruiting 18 years to 45 years.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03005.
LY03005; Placebo

Healthy Volunteer Clinical Trial using GDC-0032

Genentech - Recruiting 18 years to 55 years.
- A Phase 1, Open-Label Study to Evaluate the Effect of Particle Size, Formulation, and Food on the Pharmacokinetics of GDC-0032 in Healthy Subjects.
GDC-0032

Healthy Men Clinical Trial using Vortioxetine 10 mg; Vortioxetine 20 mg; Escitalopram 15 mg; Placebo

H. Lundbeck A/S - Recruiting 18 years to 45 years.
- Interventional, Randomised, Double-blind, Placebo-controlled, Active Comparator, Four-way Crossover Electroencephalography Study Investigating the Effects of Vortioxetine (Lu AA21004) in Healthy Male Subjects.
Vortioxetine 10 mg; Vortioxetine 20 mg; Escitalopram 15 mg; Placebo

Healthy Subjects Without Cardiovascular Disease or Terminal Illne Clinical Trial using Smartphone with APP; Counseling on lifestyles

Fundacion para la Investigacion y Formacion en Ciencias de la Salud - Recruiting 20 years to 70 years.
- Effectiveness of the Use of a Mobile Tool Added to a Standard Intervention in Improving Lifestyles in Adults.
Smartphone with APP; Counseling on lifestyles

Schizophrenia Clinical Trial using ITI-214 Dose A; ITI-214 Dose B; ITI-214 Dose C; ITI-214 Dose D (Elderly); Placebo; ITI-214 Dose E; ITI-214 Dose F; ITI-214 Dose G; ITI-214 Dose H

Takeda - Recruiting 18 years or older.
- A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214.
ITI-214 Dose A; ITI-214 Dose B; ITI-214 Dose C; ITI-214 Dose D (Elderly); Placebo; ITI-214 Dose E; ITI-214 Dose F; ITI-214 Dose G; ITI-214 Dose H

Influenza, or Flu Clinical Trial using Anti-influenza IVIG

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects.
Anti-influenza IVIG

Kidney Failure, Chronic Clinical Trial using ticagrelor

AstraZeneca - Recruiting 18 years to 80 years.
- A Single Dose, Randomized, Open-Label, Parallel Group Study Comparing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ticagrelor in Hemodialyisis Patients to Subjects With Normal Renal Function.
ticagrelor

Normal Hepatic Function,, or Impaired Hepatic Function Clinical Trial using LDE225

Novartis - Recruiting 18 years to 65 years.
- A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function..
LDE225

Weight Gain, Healthy Subjects, Obesity, or Women Clinical Trial using Linoleic Acid; Docosahexaenoic Acid; Eicosapentaenoic Acid

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- Dietary Linoleic Acid Regulation of Omega-3HUFA Metabolism: Satiety and Body Composition Among Overweight Female Subjects.
Linoleic Acid; Docosahexaenoic Acid; Eicosapentaenoic Acid

Influenza Clinical Trial using AVI-7100 versus placebo

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 60 years.
- A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects.
AVI-7100 versus placebo

Immunosuppression, Healthy, or Healthy Subjects Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Effects of Systemically Administered Hydrocortisone on the Human Immunome in Healthy Volunteers.

Neuromuscular Disease, Motor Neuron Disease, Inherited Neuromuscu Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Electrical Impedance Myography: Exploratory Studies in Normal Subjects and Patients With Neuromuscular Disorders.

Healthy Clinical Trial using JNJ-56021927 capsule; JNJ-56021927 tablet

Janssen Research & Development, LLC - Recruiting 18 years to 55 years.
- A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 Under Fasted Conditions in Healthy Male Subjects.
JNJ-56021927 capsule; JNJ-56021927 tablet

Cystic Fibrosis Clinical Trial using Lumacaftor; Lumacaftor Placebo; Ivacaftor; Ivacaftor Placebo; moxifloxacin hydrochloride

Vertex Pharmaceuticals Incorporated - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy Subjects.
Lumacaftor; Lumacaftor Placebo; Ivacaftor; Ivacaftor Placebo; moxifloxacin hydrochloride

Healthy Clinical Trial using AZD8848; Placebo

AstraZeneca - Recruiting 18 years to 45 years.
- A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects.
AZD8848; Placebo

Healthy Volunteer Clinical Trial using RO6864018

Hoffmann-La Roche - Recruiting 21 years to 65 years.
- A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO6864018 FOLLOWING ORAL ADMINISTRATION IN ASIAN HEALTHY SUBJECTS.
RO6864018

Healthy Volunteers Clinical Trial using CANA/MET XR FDC

Janssen Research & Development, LLC - Recruiting 18 years to 55 years.
- An Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics of Canagliflozin (JNJ-28431754) and Metformin Following Once-Daily Administration of 2 Canagliflozin/Metformin XR (150/1,000-mg) Fixed Dose Combination Tablets in Healthy Subjects.
CANA/MET XR FDC

Healthy Clinical Trial using JNJ-42165279; Itraconazole

Janssen Pharmaceutica N.V., Belgium - Recruiting 18 years to 55 years.
- A Study to Investigate the Potential Effects of Repeated Administration of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Subjects.
JNJ-42165279; Itraconazole

Healthy Clinical Trial using Lesinurad 400 mg; [14C]lesinurad (100 æg per 10 mL)

Ardea Biosciences, Inc. - Recruiting 18 years to 55 years.
- A Phase 1, Open-Label Study to Assess the Absolute Bioavailability of a Single Oral Dose of Lesinurad With Respect to an Intravenous Micro Tracer Dose of [14C]Lesinurad in Healthy Adult Male Subjects.
Lesinurad 400 mg; [14C]lesinurad (100 æg per 10 mL)

Pulmonary Disease, Chronic Obstructive Clinical Trial using GSK2256294

GlaxoSmithKline - Recruiting 18 years or older.
- A Study to Evaluate the Effect of Age, Food and Gender on Tolerability and Pharmacokinetics of GSK2256294 Following a Single Oral Administration in Healthy Fed and Fasted Elderly Subjects. This Study Will Also Evaluate the Biliary Metabolites in Healthy Young Males Following a Single Dose of GSK2256294.
GSK2256294

Healthy Subjects Clinical Trial using MEDI8111; Placebo

AstraZeneca - Recruiting 18 years to 40 years.
- A Phase I, Single-blind, Randomised, Placebo-controlled, Single Centre Study to Investigate the Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses in Healthy Male Subjects.
MEDI8111; Placebo

Hypersensitivity, or Anaphylaxis Clinical Trial using Sugammadex; Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years to 55 years.
- A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects.
Sugammadex; Placebo

Alzheimer's Disease Clinical Trial using AZD3293; Placebo; Moxifloxacin

AstraZeneca - Recruiting 18 years to 55 years.
- A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects.
AZD3293; Placebo; Moxifloxacin

Renal Impairment, Renal Insufficiency, Kidney Disease, or Kidney Clinical Trial using IDN-6556

Conatus Pharmaceuticals Inc. - Recruiting 18 years to 75 years.
- An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Severe Renal Impairment and in Matched Healthy Volunteers.
IDN-6556

Asthma Clinical Trial using AMG 282; AMG 282 Matching Placebo

Amgen - Recruiting 18 years to 45 years.
- A Randomized, Double-Blind, Placebo-controlled, Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Mild Atopic Asthma.
AMG 282; AMG 282 Matching Placebo

Diabetes, or Healthy Clinical Trial using semaglutide

Novo Nordisk - Recruiting 45 years to 64 years.
- A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects.
semaglutide

Stroke Clinical Trial using JPI-289; Placebo

Jeil Pharmaceutical Co., Ltd. - Recruiting 19 years to 55 years.
- A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled,Single Dose, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of JPI-289 in Healthy Male Subjects..
JPI-289; Placebo

Healthy Volunteer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- MULTI-CENTER COGNITION ASSESSMENT IN HEALTHY SUBJECTS TO COLLECT REFERENCE DATA FOR COMPARISON TO PATIENTS WITH DEPRESSION.

Healthy Volunteers, or Pharmacologic Action Clinical Trial using AZD3293 oral solution; AZD3293 tablet formulation A; AZD3293 tablet formulation B

AstraZeneca - Recruiting 18 years to 55 years.
- A Phase 1, Open-label, Randomized, Single-dose, 3-period Cross-over, Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects.
AZD3293 oral solution; AZD3293 tablet formulation A; AZD3293 tablet formulation B

Healthy Clinical Trial using PF-06263726; Placebo

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Third-Party Open, Placebo-Controlled, Multiple Dose Escalation, Parallel Group Study To Evaluate Local Tolerability, Safety And Pharmacokinetics Of Topically Applied PF-06263276 In Healthy Subjects.
PF-06263726; Placebo

Safety,, Tolerability,, or Healthy Subjects Clinical Trial using AZD8848; Placebo to match AZD8848

AstraZeneca - Recruiting 18 years to 50 years.
- A Phase 1, Single Centre, Double-blind, Randomised, Placebo-controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Administration of Multiple Ascending (MAD) Once Weekly Inhaled Doses of AZD8848 in Healthy Subjects.
AZD8848; Placebo to match AZD8848

Healthy, or Hepatic Impairment Clinical Trial using cabozantinib

Exelixis - Recruiting 18 years to 70 years.
- A Phase I, Open-Label, Parallel-Group, Single-Dose Study to Assess the Pharmacokinetics of XL184 (Cabozantinib) Capsules in Hepatic Impaired Adult Subjects.
cabozantinib

Migraine Clinical Trial using PF-05180999; Placebo; 120 mg MR PF-05180999; 360 mg MR PF-05180999; 10 mg cetirizine

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Placebo-Controlled, Crossover, Subject- And Investigator-Blind, Sponsor-Open Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of A Modified-Release Formulation Of PF-05180999 In Healthy Adult Subjects.
PF-05180999; Placebo; 120 mg MR PF-05180999; 360 mg MR PF-05180999; 10 mg cetirizine

Healthy Clinical Trial using BI 695501; adalimumab-EU source; adalimumab-US source

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years to 55 years.
- Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Double-blind, Single Dose, Parallel-arm, Active Comparator Clinical Phase I Study.
BI 695501; adalimumab-EU source; adalimumab-US source

Renal Impairment Clinical Trial using Nalmefene 18 mg

H. Lundbeck A/S - Recruiting 18 years to 70 years.
- An Interventional, Single-site, Open-label, Four-group, Single-dose Study Investigating the Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment (Mild, Moderate, or Severe) and in Healthy Subjects.
Nalmefene 18 mg

Hepatitis C Clinical Trial using TD-6450; Placebo

Theravance, Inc. - Recruiting 18 years to 60 years.
- A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of TD-6450, a NS5A Inhibitor, in Healthy Subjects.
TD-6450; Placebo

Blood Donation, Cellular Therapies, or Tissue Procurement Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Blood From Healthy Volunteers and Clinical Research Subjects for the Production of Clinical Grade Induced Pluripotent Stem Cell (iPSC) Products.

Healthy Clinical Trial using Fish Oil; Safflower Oil; Ethanol; Omega-3 polyunsaturated fatty acids; Omega-6 polyunsaturated fatty acid

University of Pennsylvania - Recruiting 21 years to 60 years.
- Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers: a Randomized Double-blinded Trial on the Modulation of the Eicosanoid and Isoprostane Pathways in Healthy Subjects by Omega-3 Polyunsaturated Fatty Acids and Red Wine..
Fish Oil; Safflower Oil; Ethanol; Omega-3 polyunsaturated fatty acids; Omega-6 polyunsaturated fatty acid

Healthy Subjects, or Hepatitis B Clinical Trial using Hepatitis B Vaccine (Recombinant)

Rockefeller University - Recruiting 18 years to 60 years.
- Effects of Persistent Innate Immune Activation on Vaccine Efficacy Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers.
Hepatitis B Vaccine (Recombinant)

Prostate Cancer Clinical Trial using Sulforadex; alpha-cyclodextrin

Evgen Pharma - Recruiting 18 years to 45 years.
- A Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Sulforadexr in Healthy Male Subjects Following Daily Dosing for 7 Days.
Sulforadex; alpha-cyclodextrin

Osteoporosis, With or Without Treatment, Bisphosphonate Treatment Clinical Trial

University of Pennsylvania - Recruiting 18 years or older.
- Biomarker Identification in Orthopaedic and Oral Maxillofacial Subjects.

Healthy Subjects Clinical Trial using E2609; itraconazole; rifampin; digoxin; donepezil

Eisai Inc. - Recruiting 18 years to 55 years.
- .
E2609; itraconazole; rifampin; digoxin; donepezil

Safety, Tolerability, Pharmacokinetics, or Cancer Clinical Trial using Dexanabinol; Placebo

e-Therapeutics PLC - Recruiting 18 years to 45 years.
- Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects.
Dexanabinol; Placebo

Hyperglycemia, or Sepsis Clinical Trial using Dopamine

Albert Einstein College of Medicine of Yeshiva University - Recruiting 18 years to 35 years.
- Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects.
Dopamine

Part 1 - Healthy Volunteers, or Part 2 - Patients With Hypertensi Clinical Trial using LFF269; Placebo to LFF269

Novartis - Recruiting 18 years to 80 years.
- A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects.
LFF269; Placebo to LFF269

Bleeding Clinical Trial using 60mg edoxaban; 180mg edoxaban; 50 IU/kg Beriplex P/N; 25 IU/kg Beriplex P/N; 10 IU/kg Beriplex P/N

Daiichi Sankyo Inc. - Recruiting 18 years to 45 years.
- A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation.
60mg edoxaban; 180mg edoxaban; 50 IU/kg Beriplex P/N; 25 IU/kg Beriplex P/N; 10 IU/kg Beriplex P/N

Infections, Papillomavirus Clinical Trial using GSK580299 (CervarixT)

GlaxoSmithKline - Recruiting 26 years or older.
- Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study.
GSK580299 (CervarixT)

Healthy Volunteer Clinical Trial using RO4995819

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects.
RO4995819

Healthy Volunteer Clinical Trial using Posaconozole; RO5424802

Hoffmann-La Roche - Recruiting 18 years to 55 years.
- An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Posaconazole, a Potent Cytochrome P450 3A Inhibitor, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects.
Posaconozole; RO5424802

Healthy Volunteer Clinical Trial using RO5545965; placebo

Hoffmann-La Roche - Recruiting 18 years to 64 years.
- A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Multiple Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects..
RO5545965; placebo

Healthy Clinical Trial using Perampanel

Eisai Inc. - Recruiting 19 years to 55 years.
- A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects.
Perampanel

Submental Fat, Safety, Efficacy, or Healthy Volunteers Clinical Trial using ATX-101; Placebo

Kythera Biopharmaceuticals - Recruiting 18 years to 65 years.
- A Multicenter, Double-blind, Placebo-controlled Safety Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects With Clinician-Reported Submental Fat Rating Scale (CR SMFRS) Grade 1 or CR-SMFRS Grade 4.
ATX-101; Placebo

Healthy Clinical Trial using 100 mg CNTO 3157; 300 mg CNTO 3157; 600 mg CNTO 3157; 300 mg CNTO 3157; Placebo

Janssen Research & Development, LLC - Recruiting 18 years to 55 years.
- A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of CNTO3157 Following an Escalating Single SC Dose to Healthy Japanese and Caucasian Subjects or a Single Intravenous Dose to Healthy Caucasian Subjects.
100 mg CNTO 3157; 300 mg CNTO 3157; 600 mg CNTO 3157; 300 mg CNTO 3157; Placebo

Rabies Clinical Trial using Active rabies vaccine (US-FDA approved); KamRAB; FDA approved commercially available HRIG product

Kamada, Ltd. - Recruiting 18 years to 75 years.
- A Prospective, Randomized, Double-Blind, Non Inferiority, Phase II/III Study of the Safety and Effectiveness of Simulated Post-Exposure Prophylaxis With Kamada Human Rabies Immune Globulin (KamRAB) With Co-administration of Active Rabies Vaccine in Healthy Subjects.
Active rabies vaccine (US-FDA approved); KamRAB; FDA approved commercially available HRIG product

Type 2 Diabetes Clinical Trial using High intensity interval training

German Diabetes Center - Recruiting 30 years to 65 years.
- Effect of High-intensity Low-volume Training on Insulin Sensitivity in Patients With Type 2 Diabetes and Healthy Lean Subjects.
High intensity interval training

Healthy Clinical Trial using E2006 2.5 mg; E2006 10 mg; E2006 25 mg; Placebo

Eisai Inc. - Recruiting 20 years to 55 years.
- A Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects.
E2006 2.5 mg; E2006 10 mg; E2006 25 mg; Placebo

Thrombocytopenia Clinical Trial using avatrombopag

Eisai Inc. - Recruiting 20 years to 55 years.
- .
avatrombopag

Meningitis, Meningococcal Clinical Trial using rLP2086 vaccine; control

Pfizer - Recruiting 10 years to 25 years.
- A Phase 3, Randomized, Active Controlled, Observer Blinded Trial to Assess the Safety and Tolerability of a Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rLP2086) Vaccine Given in Healthy Subjects Aged ò10 to <26 Years.
rLP2086 vaccine; control

Meningococcal Disease Clinical Trial using Novartis Meningococcal ACWY Conjugate Vaccine

Novartis - Recruiting 2 years to 55 years.
- A Multicenter Post Marketing Surveillance Study to Monitor the Safety of Novartis Meningococcal ACWY Conjugate Vaccine(MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects From 2 to 55 Years of Age in the Republic of South Korea..
Novartis Meningococcal ACWY Conjugate Vaccine

Healthy Clinical Trial using PF-06410293; Humira (adalimumab-EU); Humira (adalimumab-US)

Pfizer - Recruiting 18 years to 55 years.
- Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06410293 and Adalimumab Sourced From US And EU Administered To Healthy Subjects.
PF-06410293; Humira (adalimumab-EU); Humira (adalimumab-US)

Influenza Clinical Trial using TIV

Novartis - Recruiting 6 Months to 4 years.
- A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to < 48 Months of Age..
TIV

Peripheral Entheses Clinical Trial using BLOOD SAMPLES; Radiographs of the sacroiliac joints; Radiographs of heels; SCAN

Assistance Publique Hopitaux De Marseille - Recruiting 18 years to 45 years.
- Ultrasonography Assessment of Peripheral Entheses in Axial Spondyloarthritis and in Healthy Subjects, Athletes or Not..
BLOOD SAMPLES; Radiographs of the sacroiliac joints; Radiographs of heels; SCAN

Clostridium Difficile Infection Clinical Trial using Clostridium difficile Toxoid Vaccine; 0.9% normal saline

Sanofi - Recruiting 40 years to 75 years.
- Safety and Immunogenicity of a Clostridium Difficile Toxoid Vaccine Administered to Healthy Adult Subjects Aged 40 to 75 Years in Japan.
Clostridium difficile Toxoid Vaccine; 0.9% normal saline

Healthy Subjects Clinical Trial using Blood Collection

Pfizer - Recruiting 18 years to 64 years.
- Blood Collection in Healthy Adult Volunteers to Obtain Serum for Use in Serum Bactericidal Activity Assay Development.
Blood Collection

Healthy Clinical Trial using JNJ-42721458 (single dose); JNJ-42721458 (multiple doses); Placebo (single dose); Placebo (multiple doses)

Janssen Research & Development, LLC - Recruiting 18 years to 55 years.
- A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single- and Multiple-Doses of JNJ-42721458 in Healthy Male Subjects.
JNJ-42721458 (single dose); JNJ-42721458 (multiple doses); Placebo (single dose); Placebo (multiple doses)

Meningococcal Vaccine Clinical Trial using rLP2086; Havrix (HAV); Saline

Pfizer - Recruiting 10 years to 18 years.
- A Phase 3, Randomized, Active-controlled, Observer-blinded Trial to Assess the Lot Consistency, Safety, Tolerability, and Immunogenicity of a Meningococcal Serogroup B Bivalent rLP2086 Vaccine in Healthy Subjects Aged ò10 to <19 Years.
rLP2086; Havrix (HAV); Saline

Plasma Concentration, or Pharmacokinetic Profile Clinical Trial using IntelliCap

AstraZeneca - Recruiting 18 years to 50 years.
- A Randomised, Open-label, 4-way Crossover Study in Healthy Subjects to Explore the Performance of IntelliCapr by Comparing Pharmacokinetic Profiles of a Probe Drug..
IntelliCap

Healthy Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 35 years.
- Pharmacokinetics and Biodistribution of Ascorbic Acid in Healthy Human Subjects.

Healthy Clinical Trial using PF-05212377

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Open-Label Study To Evaluate 5-HT2a Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]MDL100907 Following Single Oral Dose Administration Of PP-05212377 (SAM-760) In Healthy Subjects.
PF-05212377

Inflammatory Disease Clinical Trial using AMG 357; Placebo

Amgen - Recruiting 25 years to 55 years.
- .
AMG 357; Placebo

Healthy Clinical Trial using JNJ-42165279 50 mg; JNJ-42165279 100 mg; JNJ-42165279 30 mg; Placebo

Janssen Research & Development, LLC - Recruiting 18 years to 85 years.
- A Double-Blind, Placebo-Controlled, Randomized, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Subjects.
JNJ-42165279 50 mg; JNJ-42165279 100 mg; JNJ-42165279 30 mg; Placebo

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide

Novo Nordisk - Recruiting 18 years to 85 years.
- Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function.
semaglutide

Vision Clinical Trial using Stendra 200 mg; Placebo

VIVUS, Inc. - Recruiting 18 years to 45 years.
- A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Parallel Study to Assess the Effects of Avanafil (STENDRAT) on Multiple Parameters of Vision, Including, But Not Limited to Visual Acuity, Intraocular Pressure, Pupillometry, and Color Vision Discrimination, in Healthy Male Subjects.
Stendra 200 mg; Placebo

Diabetes Mellitus, Type 2 Clinical Trial using Placebo - Capsule; LY3108743 - Capsule; Placebo - Solution; LY3108743 - Solution

Eli Lilly and Company - Recruiting 21 years to 65 years.
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY3108743 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
Placebo - Capsule; LY3108743 - Capsule; Placebo - Solution; LY3108743 - Solution

Healthy Clinical Trial using GSK2336805 30 mg; GSK2336805 60 mg; GSK2336805 120 mg; TMC435 150 mg (Treatment A); GSK2336805 60 mg (Treatment B and part of Treatment C and D); TMC435 100 mg (part of Treatment C); TMC435 150 mg (part of treatment D)

Janssen R&D Ireland - Recruiting 20 years to 55 years.
- A Phase 1, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GSK2336805 (Part 1), Followed by an Open-label, Randomized, 4-way Crossover Study to Evaluate Short-term Safety, Tolerability and Pharmacokinetics of the Co-administration of TMC435 and GSK2336805 at Steady-state (Part 2), in Healthy Japanese Subjects.
GSK2336805 30 mg; GSK2336805 60 mg; GSK2336805 120 mg; TMC435 150 mg (Treatment A); GSK2336805 60 mg (Treatment B and part of Treatment C and D); TMC435 100 mg (part of Treatment C); TMC435 150 mg (part of treatment D)

Healthy Volunteers Clinical Trial using LY2969822; Placebo

Eli Lilly and Company - Recruiting 21 years or older.
- A Single- and Multiple-Ascending Dose, Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Study of LY2969822 in Healthy Subjects.
LY2969822; Placebo

Age Related Cognitive Decline, or Age Related Macular Degeneratio Clinical Trial using Walnuts; habitual diet

Loma Linda University - Recruiting 65 years to 75 years.
- Effect of Daily Ingestion of Walnuts for 2 Years on Age-related Cognitive Decline and Macular Degeneration in Healthy Elderly Subjects: A Randomized, Single Blind, Dual Center, Controlled Trial.
Walnuts; habitual diet

Healthy Clinical Trial using Lu AE58054

H. Lundbeck A/S - Recruiting 21 years to 55 years.
- Interventional, Open-label Study Investigating the Absolute Bioavailability of Lu AE58054 After Multiple Oral Dosing and a Single Radio-labelled Intravenous Micro-dose as Well as the Contribution of Cytochrome P450 2D6 to the Exposure of Lu AE58054 in Healthy Subjects.
Lu AE58054

Atopic Dermatitis Clinical Trial using LEO 39652 cream; cream vehicle

LEO Pharma - Recruiting 18 years to 65 years.
- A Phase I, First-in-Human, Vehicle Controlled, Single Ascending Dose Trial Evaluating the Safety, Tolerability and Pharmacokinetics in Male Subjects With AD and in Healthy Male Subjects of Cutaneous Application of LEO 39652 Cream.
LEO 39652 cream; cream vehicle

Asthma and Allergic Rhinitis Clinical Trial using Montelukast; Montelukast sodium

PharmaKing - Recruiting 20 years to 45 years.
- A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Compare the Safety and the Pharmacokinetic Characteristics of MKT-N2 (Montelukast) and Singulairr (Montelukast Sodium) Tablet 10mg in Healthy Male Korean Subjects.
Montelukast; Montelukast sodium

Type 2 Diabetes or Obesity Without Diabetes Clinical Trial using Measure the threshold of detection for linoleic acid; Oral stimulation tests; Venous blood samples; Samples for genetic studies (ancillary study)

Centre Hospitalier Universitaire Dijon - Recruiting 18 years or older.
- Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients..
Measure the threshold of detection for linoleic acid; Oral stimulation tests; Venous blood samples; Samples for genetic studies (ancillary study)

Healthy Subjects Clinical Trial using Grape juice R@isol; Commercially-available grape juice

Centre Hospitalier Universitaire Dijon - Recruiting 18 years to 50 years.
- Study of the Impact of the Regular Consumption of Polyphenol-rich Grape Juice on the Biological Parameters of Oxidative Stress and on Endothelial Function in Healthy Subjects: a Prospective Randomised Double-blind Study.
Grape juice R@isol; Commercially-available grape juice

Safety, Tolerability, or Pharmacokinetics of ASP7962 Clinical Trial using ASP7962; Placebo

Astellas Pharma Inc - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Subject- and Investigator-blinded, Sponsor-unblinded, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of ASP7962, Including a Food-effect Evaluation in Healthy Subjects.
ASP7962; Placebo

Dengue Clinical Trial using TetraVax-DV Vaccine - Admixture TV003; TetraVax-DV Vaccine - Admixture TV005; Placebo

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 50 years.
- A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-experienced Adult Subjects.
TetraVax-DV Vaccine - Admixture TV003; TetraVax-DV Vaccine - Admixture TV005; Placebo

Healthy Volunteers Clinical Trial using Esketamine

Janssen Research & Development, LLC - Recruiting 20 years to 55 years.
- An Open-label, Single-Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Subjects.
Esketamine

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide; placebo; metformin; warfarin

Novo Nordisk - Recruiting 18 years to 55 years.
- An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects.
semaglutide; placebo; metformin; warfarin

Anesthesia Clinical Trial using AR09; placebo

Arbor Pharmaceuticals, Inc. - Recruiting 18 years to 50 years.
- A Phase I, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects.
AR09; placebo

Infections, Papillomavirus Clinical Trial using CervarixTM (GSK580299)

GlaxoSmithKline - Recruiting 26 years or older.
- Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the GSK HPV-023 Study.
CervarixTM (GSK580299)

Healthy Clinical Trial using PF-06252616; Placebo; PF-06252161

Pfizer - Recruiting 18 years to 64 years.
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06252616 In Healthy Subjects.
PF-06252616; Placebo; PF-06252161

Healthy Volunteers Clinical Trial using LY3127760; Celecoxib; Placebo

Eli Lilly and Company - Recruiting 18 years to 65 years.
- A Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY3127760 in Healthy Subjects.
LY3127760; Celecoxib; Placebo

Alzheimer's Disease Clinical Trial using florbetapir F 18; 18F-AV-1451

Avid Radiopharmaceuticals - Recruiting 20 years or older.
- An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease.
florbetapir F 18; 18F-AV-1451

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide

Novo Nordisk - Recruiting 18 years to 85 years.
- Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217) in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
semaglutide

Autoimmune Diseases, Sickle Cell Disease, or Chronic Graft Versus Clinical Trial using Acoustic Radiation Force Impulse (ARFI); Laser Doppler Flowmetry (LDF); Laser Doppler Perfusion Imaging (LDI); Optical Coherence Tomography (OCT); Orthogonal Polarization Spectral Imaging (OPSI); Nail fold video capillaroscopy (NVC)

Duke University - Recruiting 18 years or older.
- Mechanistic Study: Non-Invasive Cutaneous Microvascular and Fibrosis Imaging of Patients With Systemic Sclerosis, Sickle Cell Disease and Chronic Graft-Versus-Host Disease (GVHD) Compared to Healthy Subjects.
Acoustic Radiation Force Impulse (ARFI); Laser Doppler Flowmetry (LDF); Laser Doppler Perfusion Imaging (LDI); Optical Coherence Tomography (OCT); Orthogonal Polarization Spectral Imaging (OPSI); Nail fold video capillaroscopy (NVC)

Diabetes Mellitus, Type 2, or Healthy Volunteers Clinical Trial using Dulaglutide; Placebo

Eli Lilly and Company - Recruiting 18 years to 75 years.
- Pharmacokinetics of a Single Dulaglutide Dose in Healthy Chinese Subjects and of Multiple Dulaglutide Doses in Chinese Patients With T2DM.
Dulaglutide; Placebo

Acne Vulgaris Clinical Trial using 0.3% GSK1940029 gel; 1% GSK1940029 gel; 0.3%/1% vehicle gel only; Sterile distilled water; 0.5% SLS in sterile distilled water; 0.1% SLS in sterile distilled water; Patch only

GlaxoSmithKline - Recruiting 18 years to 65 years.
- A Single-Blind Study to Evaluate the Irritation Potential of Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects and Acne Patients.
0.3% GSK1940029 gel; 1% GSK1940029 gel; 0.3%/1% vehicle gel only; Sterile distilled water; 0.5% SLS in sterile distilled water; 0.1% SLS in sterile distilled water; Patch only

Prehypertension Clinical Trial using Marealis refined peptide concentrate; Placebo

KGK Synergize Inc. - Recruiting 30 years to 75 years.
- A Randomized, Double-blind, Placebo Controlled, Parallel Study for the Assessment of Anti-hypertensive Effect and Safety of Marealis RPC (Refined Peptide Concentrate), in Healthy Subjects With Mild or Moderate Hypertension.
Marealis refined peptide concentrate; Placebo

Elderly Subjects Clinical Trial using Stimulation; SHAM

Charite University, Berlin, Germany - Recruiting 50 years to 80 years.
- Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Nocturnal Slow Wave Sleep in Elderly Healthy Subjects.
Stimulation; SHAM

Infection, Human Immunodeficiency Virus Clinical Trial using DTG; CBZ

ViiV Healthcare - Recruiting 18 years to 65 years.
- A Phase I, Open Label, Randomized, Three Period, Fixed Sequence Crossover Study to Evaluate the Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (200901).
DTG; CBZ

Anesthesia Clinical Trial using Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

St. Renatus, LLC - Recruiting 3 years to 17 years.
- A Single-Center, Study Evaluating The Pharmacokinetics Of Tetracaine, Para-Butylaminobenzoic Acid, And Oxymetazoline After Intranasal Administration Of Kovacaine Mist To Healthy Pediatric Subjects.
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

Alzheimer's Disease Clinical Trial using [11C]PIB

Johns Hopkins University - Recruiting 18 years to 80 years.
- '[11C] PIB Comparison Study to [18F] AV-45 in Subjects With Alzheimer's Disease (AD) and Age Matched Healthy Controls'.
[11C]PIB

Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, O Clinical Trial using fMRI; bladder filling; bladder cooling; additional post-treatment fMRI scan

University of Zurich - Recruiting 18 years to 55 years.
- The Bladder and the Brain - Investigation of the Supraspinal Neural Control of Lower Urinary Tract Function in Healthy Subjects and Patients With Neurogenic and Non-neurogenic Bladder Dysfunction Using Advanced Neuroimaging Techniques.
fMRI; bladder filling; bladder cooling; additional post-treatment fMRI scan

Hepatic Impairment Clinical Trial using Sativex

GW Pharmaceuticals Ltd. - Recruiting 18 years or older.
- An Open Label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics and Tolerability of a Single Oromucosal Dose of 4 Sprays of Sativex(Containing 10.8 mg Delta-9-tetrahydrocannabinol [THC] and 10 mg Cannabidiol [CBD]) in Patients With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function..
Sativex

Airway Complication of Anaesthesia, or Healthy Clinical Trial using Propofol; Sevoflurane

Massachusetts General Hospital - Recruiting 18 years to 45 years.
- The Effects of Sevoflurane, Propofol, and Carbon Dioxide 'Reversal' on Upper Airway Collapsibility in Healthy, Adult Subjects.
Propofol; Sevoflurane

Healthy Clinical Trial using P7435; Placebo

Piramal Enterprises Limited - Recruiting 18 years to 60 years.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects..
P7435; Placebo

Infections, Bacterial Clinical Trial using GSK1322322 Initial fit for purpose tablets; GSK1322322 over granulated tablets; GSK1322322 intended commercial tablets; Placebo tablets; 13C-GSK1322322 stable isotope powder; GSK1322322 for injection; Placebo injection

GlaxoSmithKline - Recruiting 18 years to 65 years.
- A Three-Part Phase I, Open-Label, Single Ascending Dose, and A Single-Blind, Placebo-Controlled, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Intravenous and Oral GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects.
GSK1322322 Initial fit for purpose tablets; GSK1322322 over granulated tablets; GSK1322322 intended commercial tablets; Placebo tablets; 13C-GSK1322322 stable isotope powder; GSK1322322 for injection; Placebo injection

Nephropathy Clinical Trial using hypertonic saline

Regional Hospital Holstebro - Recruiting 18 years to 45 years.
- Effect of Thiazide, Amiloride and Hypertonic Saline on Sodium- and Water Channel Activity in the Nephron in Healthy Subjects Estimated by Urinary Biomarkers.
hypertonic saline

Intraocular Pressure, or Caffeine Dosage Clinical Trial using decaffeinated coffee; regular dose coffee; high dose coffee

Chiang Mai University - Recruiting 20 years to 35 years.
- The Effect of Dosage of Caffeine on Intraocular Pressure in Healthy Subjects.
decaffeinated coffee; regular dose coffee; high dose coffee

Type 2 Diabetes Clinical Trial using 18F-AV-133; 10% Arginine Hydrochloride-R-Gene 10

Avid Radiopharmaceuticals - Recruiting 30 years to 65 years.
- Quantitative PET Imaging of Pancreatic Beta-Cell Mass in Healthy Overweight/Obese Subjects, Subjects With Prediabetes, and Type 2 Diabetes Patients With 18F-FP-DTBZ (18F-AV-133).
18F-AV-133; 10% Arginine Hydrochloride-R-Gene 10

Healthy Male Volunteers Clinical Trial using micronized fenofibrate 160mg; pitavastatin Ca 2mg; micronized fenofibrate 160mg plus pitavastatin Ca 2mg

Hanlim Pharm. Co., Ltd. - Recruiting 20 years to 55 years.
- Open-label, Randomized, Repeated Dosing Crossover Study to Evaluate the Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin in Healthy Adult Subjects.
micronized fenofibrate 160mg; pitavastatin Ca 2mg; micronized fenofibrate 160mg plus pitavastatin Ca 2mg

CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, or HEALTHY SUBJECT Clinical Trial using SALBUTAMOL

Imperial College London - Recruiting 18 years or older.
- Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD).
SALBUTAMOL

QT Interval Prolongation Clinical Trial using moxifloxacin; moxifloxacin-placebo

Peking University Third Hospital - Recruiting 20 years to 45 years.
- A Single-center, Randomized, Double-blinded, 2-way Crossover, Placebo-controlled Study to Assess the QT/QTc Interval After Administration of Single Oral Dose of 400mg Moxifloxacin in Healthy Chinese Subjects.
moxifloxacin; moxifloxacin-placebo

Deep Vein Thrombosis Leg, or Stroke (in Patients With Atrial Fibr Clinical Trial using DPOC-4088; Placebo

Diakron Pharmaceuticals - Recruiting 18 years to 50 years.
- A Randomized, Double-blind, Placebo-controlled, Stepwise Study of the Pharmacokinetics (PK), Pharmacodynamics (PD), PK/PD Characteristics and Safety of Multiple Once-daily Oral Dosing of DPOC-4088 in Healthy Young Male Subjects.
DPOC-4088; Placebo

COPD Patients, Healthy Subjects, Semi-supine Echo (SSE), Flow-med Clinical Trial using Measure pulmonary artery pressure change during exercise; Pulmonary pressure response during exercise

Szeged University - Recruiting 45 years to 70 years.
- Pulmonary Arterial Pressure Response During Exercise in COPD and Healthy Subjects.
Measure pulmonary artery pressure change during exercise; Pulmonary pressure response during exercise

Hypoosmolality, Hyperosmolality, or Renal Failure Clinical Trial

Hospital Centre Biel/Bienne - Recruiting 18 years to 80 years.
- Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion.

Cancer, or Vomiting Clinical Trial

Taipei Medical University WanFang Hospital - Recruiting 20 years to 40 years.
- An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects.

Healthy Subjects, or Anemia Clinical Trial using Fundus photography, cubital blood draw

Triemli Hospital - Recruiting 18 years to 90 years.
- Non- Invasive Measurement of the Absolute Hemoglobin Value in the Retinal Arteries of Anemic and Healthy Subjects Using a New Approach.
Fundus photography, cubital blood draw

Age Related Macular Degeneration Clinical Trial

Medical University of Vienna - Recruiting 18 years to 90 years.
- Macular Pigment Optical Density in Healthy Subjects.

Diabetes Mellitis Type 2 Clinical Trial using DA-1229; Placebo

Dong-A Pharmaceutical Co., Ltd. - Recruiting 20 years to 45 years.
- A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Phase 1 Study to Investigate the Safety, Tolerance, and Pharmacokinetics/Pharmacodynamics of DA-1229 in Healthy Male Subjects.
DA-1229; Placebo

Pulmonary Diffusing Capacity Clinical Trial using Nitric oxide, Carbon monoxide, Helium

University Hospital Tuebingen - Recruiting 6 years to 45 years.
- Development of a New Method for Steady-State Measurement of NO Lung Diffusing Capacity in Healthy Subjects.
Nitric oxide, Carbon monoxide, Helium

Chronic Obstructive Airway Disease, or Healthy Volunteers Clinical Trial using Up to 100ml blood will be taken by venupuncture.

Imperial College London - Recruiting 21 years to 75 years.
- Regulation of the Release of Inflammatory Mediators From Blood Leukocytes: A Comparison of Healthy Subjects, Healthy Smokers and Patients With COPD..
Up to 100ml blood will be taken by venupuncture.